BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 19318552)

  • 21. Antiproliferative effects of γ-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action.
    Hu J; Zhu X; Lu Q
    J Int Med Res; 2013 Aug; 41(4):1017-26. PubMed ID: 23839278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.
    Joshi I; Minter LM; Telfer J; Demarest RM; Capobianco AJ; Aster JC; Sicinski P; Fauq A; Golde TE; Osborne BA
    Blood; 2009 Feb; 113(8):1689-98. PubMed ID: 19001083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
    Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
    Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
    Srethapakdi M; Liu F; Tavorath R; Rosen N
    Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances on NOTCH signaling in T-ALL.
    Tzoneva G; Ferrando AA
    Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I.
    Iwanaga R; Ohtani K; Hayashi T; Nakamura M
    Oncogene; 2001 Apr; 20(17):2055-67. PubMed ID: 11360190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
    Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
    Franciosa G; Smits JGA; Minuzzo S; Martinez-Val A; Indraccolo S; Olsen JV
    Nat Commun; 2021 May; 12(1):2507. PubMed ID: 33947863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia.
    Kaushik B; Pal D; Saha S
    Curr Drug Targets; 2021; 22(15):1789-1798. PubMed ID: 33538669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anti-malarial drug chloroquine sensitizes oncogenic NOTCH1 driven human T-ALL to γ-secretase inhibition.
    Hounjet J; Habets R; Schaaf MB; Hendrickx TC; Barbeau LMO; Yahyanejad S; Rouschop KM; Groot AJ; Vooijs M
    Oncogene; 2019 Jul; 38(27):5457-5468. PubMed ID: 30967635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome.
    Pui CH
    Cancer Cell; 2009 Feb; 15(2):85-7. PubMed ID: 19185842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
    López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
    Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic antileukemic therapies in
    Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
    Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
    Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.
    Dastur A; Choi A; Costa C; Yin X; Williams A; McClanaghan J; Greenberg M; Roderick J; Patel NU; Boisvert J; McDermott U; Garnett MJ; Almenara J; Grant S; Rizzo K; Engelman JA; Kelliher M; Faber AC; Benes CH
    Clin Cancer Res; 2019 Jan; 25(1):312-324. PubMed ID: 30224339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel mechanism of transcriptional repression of p27kip1 through Notch/HRT2 signaling in vascular smooth muscle cells.
    Havrda MC; Johnson MJ; O'Neill CF; Liaw L
    Thromb Haemost; 2006 Sep; 96(3):361-70. PubMed ID: 16953280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
    Timme CR; Gruidl M; Yeatman TJ
    Apoptosis; 2013 Oct; 18(10):1163-74. PubMed ID: 23887890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
    Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP
    Blood; 2010 Feb; 115(6):1175-84. PubMed ID: 20008304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
    Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
    Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.